Long-survival in Responding Patients with Metastatic Breast Cancer Treated with Doxorubicin-Docetaxel Combination

• Published in: Anticancer research 2004-09, Vol.24 (5B), p.3257
• Main Authors: R. MATTIOLI, P. LIPPE, C. MASSACESI, C. CAPPELLETTI, D. NACCIARRITI, R. BISONNI, F. GRAZIANO, E.T. MENICHETTI, L. IMPERATORI, E. TESTA, G. LAICI, A. BALLETTA, R.R. SILVA
• Format: Article
• Language: English
• ISSN: 0250-7005; 1791-7530

Background: The doxorubicin-docetaxel combination is active in breast cancer; the aim of the present study was to evaluate the complete response rate and safety profile of the doxorubicin and docetaxel regimen as first-line chemotherapy in metastatic breast cancer patients. Patients and Methods: Forty-three patients entered the study. Treatment plan was: doxorubicin (50 mg/m 2 , i.v. bolus) followed 1 hour later by docetaxel (75 mg/m 2 , i.v. infusion over 1 hour), q 3 weeks, for up to six courses. The patients achieving a response or a stabilisation of disease after 6 courses were allowed to intensify the treatment with docetaxel (100 mg/m 2 , q 3 weeks) for up to 2 courses. G-CSF (or GM-CSF) was administered if clinically indicated. Results: Patients' median age was 57 years (range 32-75) and 72% of them had visceral disease. A total of 217 doxorubicin-docetaxel courses were delivered, with 70% of patients receiving all the 6 planned cycles. Among the 40 patients assessable for response (WHO criteria), 7 (16%) achieved a complete remission and 22 (51%) a partial remission, for an overall response rate (intent-to-treat) of 67% (95% C.I.=53% to 81%). In 19 patients, the treatment was intensified with two more single-agent docetaxel cycles, without ameliorating the response. Twenty-seven patients with oestrogen receptor-positive received hormonal therapy as ‘maintenance’ after completing chemotherapy treatment. NCIC G3-G4 neutropenia was recorded in 58% of patients, with G/GM-CSF used in 23 (53%) patients and 91 (38%) cycles. No patients experienced severe cardiac or neurological toxicity. No toxic death occurred. With a median follow-up of 41 months among alive patients, we observed in responder patients an overall median time to progression and survival of 18 and 33 months respectively, with ten long-survivors still alive. Conclusion: This study confirmed the combination doxorubicin-docetaxel as a very active regimen for metastatic breast cancer. Remarkably long survival times were observed not only in complete responders, but also in those patients who responded partially. This might be equally attributed to first-line treatment and sequential maintenance hormonal therapy.